Loading…

A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

Saved in:

Bibliographic Details
Published in:	Leukemia & lymphoma 2023-01, Vol.64 (2), p.473-477
Main Authors:	Assouline, Sarit, Michaelis, Laura C., Othus, Megan, Hay, Annette E., Walter, Roland B., Jacoby, Meagan A., Schroeder, Mark A., Uy, Geoffrey L., Law, Lisa Y., Cheema, Faisal, Sweet, Kendra L., Asch, Adam S., Liu, Jijun (Jane), Moseley, Anna B., Maher, Tracy, Kingsbury, Laura L., Fang, Min, Radich, Jerald, Little, Richard F., Erba, Harry P.
Format:	Article
Language:	English
Subjects:	Azacitidine - adverse effects Humans Leukemia, Myeloid, Acute - chemically induced Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - drug therapy Leukemia, Myelomonocytic, Chronic - diagnosis Leukemia, Myelomonocytic, Chronic - drug therapy Middle Aged Myelodysplastic Syndromes - diagnosis Myelodysplastic Syndromes - drug therapy Nivolumab - therapeutic use
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!